Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience.
Arialys Therapeutics has raised $58.0M in total funding. The most recent round was Seed. The last funding was announced in September 2023.
Arialys Therapeutics's investors include MPM Capital, Alexandria Venture Investments, Johnson & Johnson Innovation JJDC, Catalys Pacific, Avalon BioVentures.
Arialys Therapeutics is headquartered in La Jolla, United States.
Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience.
Arialys Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Arialys Therapeutics — Funding & Investors." VCBacked, September 12, 2023, https://www.vcbacked.co/company/arialys-therapeutics. Accessed August 1, 2026.
VCBacked. (2023). Arialys Therapeutics — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/arialys-therapeutics
{{cite web |title=Arialys Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/arialys-therapeutics |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated